Skip to main content

LLS Research Now

A monthly video conference series about how you and LLS are advancing blood cancer research in the quest for cures.

With hosts Drs. Lou DeGennaro, Gwen Nichols and Lee Greenberger


Upcoming Calls:

Recent Advances & FDA Approvals for Blood Cancer

Thursday, February 24 at 2:00PM ET / 11:00 PT

Registration Here

Hosted by
Louis J. DeGennaro, PhD, LLS President and Chief Executive Officer
Moderated by
Lee Greenberger, PhD, LLS Chief Scientific Officer

In the past year we have seen important advances for blood cancer patients, including several landmark FDA approvals.

Join us as we welcome a panel of esteemed researchers to look back at the progress from this past year and what it means for patients now and in the future. We will also review the FDA approvals from 2021 and what’s likely to be approved in 2022, and provide an update on recent findings from LLS’s National Patient Registry COVID-19 project.

Panelists:

Elizabeth Budde, MD, PhD (City of Hope) is a well-recognized clinical expert and researcher in lymphoma and leukemia. As a physician scientist, Dr. Budde leads a group of researchers in designing and investigating the use of immunotherapies. She serves as a member on several national committees, including the National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma and the Alliance of American Cancer Institute CAR T Working Group. Devoted to developing promising new treatments for patients, she is the principal investigator on innovative translational research protocols and maintains a dynamic portfolio of clinical trials.

Larry Saltzman, MD (Director of the LLS National Patient Registry) is a family physician and CLL survivor. Leading LLS’s National Patient Registry, a project of the Michael J. Garil Data Collective, Dr. Saltzman is reviewing patient-submitted clinical data and analyzing results to understand risk for infection and immune response to vaccination in blood cancer patients.

Eytan Stein, MD (Memorial Sloan Kettering Cancer Center) specializes in caring for people with acute and chronic leukemias, myelodysplastic syndromes and myeloprolifterative neoplasms. An active clinical researcher, Dr. Stein develops new and innovative approaches to treating acute myeloid leukemia (AML) and is the principal investigator on a wide variety of clinical trials that are aimed at more precisely and effectively targeting cancer. In the past several years, Dr. Stein led trials that resulted in FDA approvals for enasidenib and ivosidenib, both novel small molecule inhibitors.